Bofanglutide is an investigational long-acting glucagon-like peptide-1 (GLP-1) receptor agonist currently under development for the management of type 2 diabetes mellitus, obesity, and overweight conditions… Read more
Bofanglutide is an investigational long-acting glucagon-like peptide-1 (GLP-1) receptor agonist currently under development for the management of type 2 diabetes mellitus, obesity, and overweight conditions with weight-related comorbidities. By mimicking the action of the endogenous GLP-1 hormone, this compound enhances glucose-dependent insulin secretion and helps suppress appetite. To support rigorous drug development, pharmaceutical laboratories require high-quality reference standards of the Bofanglutide active pharmaceutical ingredient, as well as stable isotope labelled compounds such as deuterated analogues. These analytical tools are essential for impurity profiling, method validation, and precise quantification during mass spectrometry-based bioanalytical assays. Utilizing these authenticated reference materials ensures compliance with quality control standards, allowing researchers to accurately monitor the stability and pharmacokinetic profile of the peptide throughout the regulatory submission process.